tiprankstipranks
Trending News
More News >
ImmuPharma plc (GB:IMM)
:IMM
UK Market
Advertisement

ImmuPharma (IMM) Income Statement

Compare
27 Followers

ImmuPharma Income Statement

Last quarter (Q2 2025), ImmuPharma's total revenue was £0.00, a decrease of ― from the same quarter last year. In Q2, ImmuPharma's net income was £-919.44K. See ImmuPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
£ 0.00£ 0.00£ 0.00£ 118.35K£ 126.67K
Gross Profit
£ -63.88K£ -37.61K£ -118.00K£ 118.35K£ 126.67K
Operating Expenses
£ 2.67M£ 3.15M£ 2.91M£ 6.71M£ 5.72M
Depreciation and Amortization
£ 63.88K£ 37.61K£ 117.56K£ 114.12K£ 170.96K
EBITDA
£ -2.61M£ -3.02M£ -2.91M£ -8.70M£ -6.84M
Operating Income
£ -2.28M£ -3.06M£ -3.03M£ -6.59M£ -5.59M
Other Income/Expenses
£ -104.00K£ -356.00K£ -1.43M£ -2.35M£ -1.66M
Pretax Income
£ -2.78M£ -3.42M£ -4.46M£ -8.94M£ -7.25M
Net Income
£ -2.48M£ -2.92M£ -3.81M£ -8.17M£ -6.86M
Per Share Metrics
Basic EPS
£ -0.01£ -0.01£ -0.01£ -0.03£ -0.03
Diluted EPS
£ -0.01£ -0.01£ -0.01£ -0.03£ -0.03
Weighted Average Shares Outstanding
413.92M 360.71M 302.91M 251.16M 200.00M
Weighted Average Shares Outstanding (Diluted)
416.44M 362.00M 302.91M 251.16M 200.18M
Currency in GBP

ImmuPharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis